Table 2.

Comparison of ACF number among the sulindac, etodolac, and placebo groups before and after treatment

BeforeaAfter 2 mo
Subjects with polypectomy
Placebo
 Mean ± SD7.77 ± 4.666.87 ± 6.03
 Median (interquartile range)7.0 (5.0–10.0)6.0 (3.0–8.5)P < 0.001b
Sulindac
 Mean ± SD7.70 ± 4.044.00 ± 2.95
 Median (interquartile range)7.0 (4.5–10.0)4.0 (1.0–6.0)
Etodolac
 Mean ± SD7.52 ± 4.016.28 ± 5.21P = 0.67
 Median (interquartile range)7.0 (4.0–10.0)5.0 (2.5–8.5)
Polyp-free subjects
Placebo
 Mean ± SD4.00 ± 1.823.90 ± 2.72
 Median (interquartile range)4.0 (2.0–6.0)3.0 (1.0–7.0)
Sulindac
 Mean ± SD4.40 ±2.212.70 ±2.16
 Median (interquartile range)4.0 (2.0–6.0)3.0 (0–4.5)P = 0.38
Etodolac
 Mean ± SD4.73 ± 2.324.10 ± 2.60P = 0.54
 Median (interquartile range)4.0 (0–5.5)4.0 (2.0–9.0)
Ali subjects
Placebo
 Mean ± SD7.12 ± 4.536.35 ± 5.69
 Median (interquartile range)6.5 (4.0–9.0)5.0 (2.3–8.0)
Sulindac
 Mean ± SD7.15 ± 3.983.77 ± 2.86P = 0.0075b
 Median (interquartile range)6.5 (4.0–9.0)4.0 (1.0–5.3)
Etodolac
 Mean ± SD7.01 ± 3.895.91 ± 4.93P = 0.73
 Median (interquartile range)6.0 (4.0–9.0)5.0 (2.0–7.5)
  • a There were no significant differences before treatment among the 3 groups by the Kruskal-Wallis test.

  • b Significant P value by Mann–Whitney U test.